Treatment with thalidomide or lenalidomide for a malignant disease

Deep vein thrombosis - Treatment with thalidomide or lenalidomide for a malignant disease Factor

Last reviewed for CCPS 22 December 2008.

Preliminary questions [40405]

40410 there is some evidence that treatment with thalidomide or lenalidomide for a malignant disease may be a factor in the development of the condition under consideration.

40419 the veteran has been treated with thalidomide or lenalidomide for a malignant disease at some time.

40420 — the malignant disease for which the veteran was treated with thalidomide or lenalidomide is an illness or injury which is identifiable.

40421 for the identified illness or injury, a malignant disease, the veteran was treated with thalidomide or lenalidomide within the 90 days before the clinical onset of the condition under consideration.

40422 — the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and VEA service for the clinical onset of deep vein thrombosis.

40423 — the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and operational service for the clinical onset of deep vein thrombosis.

or

40424 — the veteran has established the causal connection between being treated with thalidomide or lenalidomide for a malignant disease and eligible service for the clinical onset of deep vein thrombosis.

Clinical onset and operational service [40423]

40425 — the identified illness or injury, a malignant disease that was treated with thalidomide or lenalidomide, is causally related to operational service.

Clinical onset and eligible service [40424]

40426 — the identified illness or injury, a malignant disease that was treated with thalidomide or lenalidomide, is causally related to eligible service.